Advertisement

Topics

BMS Shareholders Greenlight Celgene Deal

00:06 EDT 17 Apr 2019 | CHEManager

Shareholders of Bristol Myers Squibb (BMS) have approved the company’s $74 billion acquisition of Celgene. At the special meeting on Apr. 12, altogether 75% of the shareholders voted in favor of the deal, 24% were against it and less than 1% abstained. The transaction is planned to complete in the third quarter.

Original Article: BMS Shareholders Greenlight Celgene Deal

NEXT ARTICLE

More From BioPortfolio on "BMS Shareholders Greenlight Celgene Deal"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...